CTOs on the Move

Guardant Health

www.guardanthealth.com

 
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Sonya Natanzon
 VP of Engineering Profile
Darya Chudova
 Chief Technology Officer Profile
Kim Green
 Director, Information Security and Compliance Profile

Funding

Guardant Health raised $100M on 01/07/2016
Guardant Health raised $360M on 05/11/2017

Similar Companies

Verdezyne

Verdezyne is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vertex Pharmaceuticals

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases.

Protein Sciences Corporation

Protein Sciences Corporation is a Meriden, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beyond Air

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.

Heat Biologics

Heat Biologics is a clinical-stage company focused on developing its proprietary ImPACT™ (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.